VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 127 filers reported holding VAXCYTE INC in Q3 2022. The put-call ratio across all filers is 0.98 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,878,859 | -1.6% | 409,550 | -3.7% | 0.00% | 0.0% |
| Q2 2023 | $21,228,995 | +232.0% | 425,090 | +149.1% | 0.00% | +100.0% |
| Q1 2023 | $6,394,949 | -20.7% | 170,623 | +1.5% | 0.00% | 0.0% |
| Q4 2022 | $8,061,114 | +689.5% | 168,115 | +295.3% | 0.00% | – |
| Q3 2022 | $1,021,000 | -65.9% | 42,533 | -69.1% | 0.00% | – |
| Q2 2022 | $2,996,000 | +39.5% | 137,671 | +54.8% | 0.00% | – |
| Q1 2022 | $2,148,000 | +56.1% | 88,931 | +53.7% | 0.00% | – |
| Q4 2021 | $1,376,000 | +42.4% | 57,843 | +51.9% | 0.00% | – |
| Q3 2021 | $966,000 | +115.1% | 38,076 | +91.6% | 0.00% | – |
| Q2 2021 | $449,000 | +140.1% | 19,876 | +109.9% | 0.00% | – |
| Q1 2021 | $187,000 | -48.1% | 9,471 | -30.1% | 0.00% | – |
| Q4 2020 | $360,000 | +146.6% | 13,559 | +358.2% | 0.00% | – |
| Q3 2020 | $146,000 | +4766.7% | 2,959 | +2859.0% | 0.00% | – |
| Q2 2020 | $3,000 | – | 100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,049,893 | $53,523,545 | 17.09% |
| Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $40,429,128 | 16.12% |
| Kynam Capital Management, LP | 1,302,407 | $66,396,709 | 10.86% |
| RA Capital Management | 7,891,254 | $402,296,129 | 7.92% |
| COMMODORE CAPITAL LP | 1,100,000 | $56,078,000 | 6.56% |
| GREAT POINT PARTNERS LLC | 531,211 | $27,081,137 | 4.93% |
| ACUTA CAPITAL PARTNERS, LLC | 121,022 | $6,169,702 | 4.14% |
| Frazier Life Sciences Management, L.P. | 1,164,405 | $59,361,367 | 3.94% |
| Novo Holdings A/S | 845,000 | $43,078,100 | 3.18% |
| BRAIDWELL LP | 1,619,553 | $82,564,812 | 2.61% |